Warren Goldblatt, MD
Ophthalmology · Portsmouth, NHNPI 1689677742
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations.
Across 109 payments — averaging $31.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Harrow Eye, LLC$538
- Glaukos Corporation$398
- Alcon$390
- AbbVie$339
- Rxsight Inc$305
- Ocular Therapeutix, Inc.$181
- plus $1K from 20 others
What the payments were for
- Speaking & faculty fees$391%
- Food & beverage$3,35298%
- Gifts$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Harrow Eye, LLC | 7 | $538 |
| Glaukos Corporation | 4 | $398 |
| Alcon | 19 | $390 |
| AbbVie(2 entities) | 13 | $339 |
| Rxsight Inc | 3 | $305 |
| Ocular Therapeutix, Inc. | 10 | $181 |
| Sun Pharmaceutical Industries Inc. | 5 | $139 |
| Aerie Pharmaceuticals, Inc. | 7 | $139 |
| Amgen | 7 | $110 |
| Boehringer Ingelheim | 1 | $109 |
| Bausch & Lomb Americas Inc. | 5 | $104 |
| Novartis | 4 | $93 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $87 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $81 |
| Carl Zeiss Meditec, Inc. | 1 | $60 |
| Sight Sciences, Inc. | 4 | $57 |
| Esperion Therapeutics, Inc. | 1 | $52 |
| NEW World Medical,inc. | 1 | $49 |
| Ivantis, Inc | 1 | $40 |
| Tearlab Corp | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Rayner Intraocular Lenses Limited | 1 | $23 |
| Genentech USA, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Dompe US, Inc. | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,411 in reported general payments places this provider in the 70th percentile of 80 ophthalmology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 41 | $24,504 |
| RestasisCyclosporine | 13 | $23,380 |
| RhopressaNetarsudil Mesylate | 32 | $19,929 |
| RocklatanNetarsudil Mesylat/Latanoprost | 11 | $9,601 |
| Travoprost | 33 | $8,083 |
| Prednisolone Acetate | 132 | $4,754 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 19 | $3,753 |
| Timolol Maleate | 78 | $2,752 |
| Latanoprost | 219 | $2,728 |
| Ketorolac Tromethamine | 66 | $2,047 |
| Brimonidine Tartrate | 90 | $1,333 |
| MoxifloxacinMoxifloxacin Hcl | 49 | $1,116 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 17 | $946 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 58 | $914 |
| Dorzolamide Hcl | 36 | $442 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis | $339 | $47,88454 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $139 | $29,53043 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 80 ophthalmology providers in New Hampshire.
Other ophthalmology in Portsmouth
- Jason SzelogPortsmouth$71K
- Jennifer LingPortsmouth$9K
- Newton PetersPortsmouth$5K
- Claudia BartoliniPortsmouth$4K
- Timothy SullivanPortsmouth$3K
- Lucian SzmydPortsmouth$2K
- Richard LasondePortsmouth$1K
- Nathaniel SearsPortsmouth$601
- Marsha KavanaghPortsmouth$371
- Dane SlentzDerry$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.